Table 1. Demographic and clinical characteristics by gender and treatment arms.
| FOLFIRINOX arm (N = 171) | Gemcitabine arm (N = 171) | ||||||
|---|---|---|---|---|---|---|---|
| Male | Female | p-value | Male | Female | p-value | ||
| (N = 106) | (N = 65) | (N = 105) | (N = 66) | ||||
| Age—yr | 0.291 | 0.607 | |||||
| Median | 60 | 62 | 61 | 61 | |||
| Range | 31–74 | 25–76 | 40–75 | 34–75 | |||
| ECOG performance status score—no. (%) | 0.134 | 0.456 | |||||
| 0 | 44 (41.5) | 19 (29.2) | 37 (35.2) | 27 (40.9) | |||
| 1 | 62 (58.5) | 45 (69.2) | 68 (64.8) | 39 (59.1) | |||
| 2 | 0 (0.0) | 1 (1.5) | 0 (0.0) | 0 (0.0) | |||
| Pancreatic tumor location—no. (%) | 0.763 | 0.996 | |||||
| Head | 43 (40.6) | 24 (37.4) | 38 (36.2) | 25 (37.9) | |||
| Body | 33 (31.1) | 20 (32.1) | 36 (34.3) | 22 (33.3) | |||
| Tail | 27 (25.5) | 18 (26.7) | 28 (26.7) | 17 (25.8) | |||
| Multicentric | 3 (2.8) | 3 (4.6) | 3 (2.9) | 2 (3.0) | |||
| Metastatic sites involved | 0.551 | 0.862 | |||||
| Median | 2 | 2 | 2 | 2 | |||
| Range | 1–6 | 1–5 | 1–6 | 1–4 | |||
| Measurable metastatic site—no. (%) | |||||||
| Liver | 92 (87.6) | 57 (89.1) | 0.778 | 93 (88.6) | 57 (86.4) | 0.669 | |
| Pancreas | 57 (54.3) | 32 (50.0) | 0.588 | 55 (52.4) | 36 (54.5) | 0.782 | |
| Lymph node | 37 (35.2) | 11 (17.2) | 0.012* | 25 (23.8) | 14 (21.2) | 0.694 | |
| Lung | 18 (17.1) | 15 (23.4) | 0.317 | 30 (28.6) | 19 (28.8) | 0.976 | |
| Peritoneal | 16 (15.2) | 17 (26.6) | 0.072 | 20 (19.0) | 12 (18.2) | 0.888 | |
| Other | 13 (12.4) | 5 (7.8) | 0.350 | 17 (16.2) | 12 (18.2) | 0.736 | |